Literature DB >> 17638093

Safety profile of ibuprofen suspension in young children.

E Ashraf1, L Ford, R Geetha, S Cooper.   

Abstract

The Children's Analgesic Medicine Project (CAMP) was a multicenter, all-comers, openlabel, prospective study to compare the safety of ibuprofen suspension with acetaminophen suspension in children with fever and/or pain. Four hundred and twenty four (424) pediatricians enrolled 41 810 children (aged 1 month to 18 years old) at 69 US clinics. Safety data included information concerning medication use and adverse events (AEs) summarized by severity and analyzed by age groups (younger and older than 2 years). Among 30 144 children who took at least one dose of ibuprofen or acetaminophen, 14 281 were younger (< 2 yrs) and 15 863 were older ([Symbol: see text] 2 to < 12 yrs). Within both age groups, the incidence rates for specific AEs, including abdominal pain, insomnia, and hyperkinesia were rare and generally < 1% for both treatments. For younger children, fever, vomiting, diarrhea, rhinitis, rash and otitis media were the only AEs with an incidence rate > 1% (in either treatment group). For older children, the only AEs with an incidence rate > 1% in either group were rhinitis, pharyngitis and otitis media. AEs were generally mild to moderate for both treatments within the two age groups. There were no serious AEs, including anaphylaxis, Reye's syndrome, renal failure, GI bleeding/perforation or necrotizing fasciitis. There was a slightly higher overall incidence of side effects in the ibuprofen group (17.6% vs. 15.0%) for the younger children; and similar results were seen in the older children (11.9% vs. 10.7%). This may have been due to the preference of physicians to treat the sicker children with ibuprofen. There were four deaths, all unrelated to study medication, all occurring in children < 2 yrs (herpes encephalitis, sepsis due to 5. pneumoniae, medulloblastoma, and sudden infant death syndrome). The safety of ibuprofen suspension in children < 2 yrs was demonstrated in this study. The safety profile in children < 2 yrs is consistent with the excellent profile observed in children [Symbol: see text] 2 yrs. Overall, ibuprofen exhibited an AE profile similar to acetaminophen in both younger and older children.

Entities:  

Year:  1999        PMID: 17638093     DOI: 10.1007/s10787-999-0005-0

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   5.093


  3 in total

Review 1.  Ibuprofen and paracetamol: relative safety in non-prescription dosages.

Authors:  K D Rainsford; S C Roberts; S Brown
Journal:  J Pharm Pharmacol       Date:  1997-04       Impact factor: 3.765

2.  Ibuprofen, acetaminophen, and placebo treatment of febrile children.

Authors:  P D Walson; G Galletta; N J Braden; L Alexander
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

3.  An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial.

Authors:  S M Lesko; A A Mitchell
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

  3 in total
  14 in total

Review 1.  Is the large simple trial design used for comparative, post-approval safety research? A review of a clinical trials registry and the published literature.

Authors:  Robert F Reynolds; Joanna A Lem; Nicolle M Gatto; Sybil M Eng
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

2.  Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis.

Authors:  Alejandro Balestracci; Mauricio Ezquer; María Eugenia Elmo; Andrea Molini; Claudia Thorel; Milagros Torrents; Ismael Toledo
Journal:  Pediatr Nephrol       Date:  2015-04-21       Impact factor: 3.714

3.  Adverse effects of a 10-day course of ibuprofen in Holstein calves.

Authors:  P Walsh; F R Carvallo Chaigneau; M Anderson; N Behrens; H McEligot; B Gunnarson; L J Gershwin
Journal:  J Vet Pharmacol Ther       Date:  2016-02-14       Impact factor: 1.786

Review 4.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

Review 5.  Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.

Authors:  Victoria C Ziesenitz; Andreas Zutter; Thomas O Erb; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

Review 6.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

7.  Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues?

Authors:  Vera E Valkhoff; René Schade; Geert W 't Jong; Silvana Romio; Martijn J Schuemie; Andrea Arfe; Edeltraut Garbe; Ron Herings; Silvia Lucchi; Gino Picelli; Tania Schink; Huub Straatman; Marco Villa; Ernst J Kuipers; Miriam C J M Sturkenboom
Journal:  BMC Pediatr       Date:  2013-11-19       Impact factor: 2.125

Review 8.  A clinical and safety review of paracetamol and ibuprofen in children.

Authors:  Dipak J Kanabar
Journal:  Inflammopharmacology       Date:  2017-01-06       Impact factor: 4.473

9.  Safety of ibuprofen in infants younger than six months: A retrospective cohort study.

Authors:  Paul Walsh; Stephen J Rothenberg; Heejung Bang
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

Review 10.  A practical approach to the treatment of low-risk childhood fever.

Authors:  Dipak Kanabar
Journal:  Drugs R D       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.